{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:02:36Z","timestamp":1790564556528,"version":"4.1.0"},"reference-count":34,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Histiocytosis encompasses Langerhans cell histiocytosis (LCH) and non-LCH, such as Erdheim\u2013Chester disease (ECD). ECD or a mixed type of histiocytosis (LCH\/ECD) may initially involve the central nervous system (CNS), resulting in a delayed diagnosis. More recently, dabrafenib and trametinib (Dab\/Tra regimen) have become available in its treatment. Case Presentation: A 46-year-old woman with CNS involvement of mixed histiocytosis (BRAF V600E-positive LCH\/ECD) was treated with combination therapy using a Dab\/Tra regimen. At initial presentation, she exhibited central diabetes insipidus, dysarthria, and gait disturbance with mild spasticity and ataxia, requiring walking assistance even for short distances. The interval from the onset of central neurological symptoms to diagnosis of mixed histiocytosis was 4 years. The introduction of targeted therapy was 2 years later. After seven months of Dab\/Tra therapy, partial neurological improvement was observed, as reflected by a decrease in the SARA score from 21\/40 to 13\/40 and the ICARS score from 33\/100 to 28\/100. However, further neurological recovery remained significantly delayed. Conclusions: We suspect that the limited improvement may be attributable to the delayed initiation of targeted therapy, in contrast to the more rapid and pronounced responses reported in cases where treatment was started earlier.<\/jats:p>","DOI":"10.3390\/reports9010018","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:46:43Z","timestamp":1767786403000},"page":"18","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Delayed Neurologic Response to Dabrafenib and Trametinib in the Case of Mixed Histiocytosis (LCH\/ECD): Case Report and Literature Review"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9795-0819","authenticated-orcid":false,"given":"Shinsaku","family":"Imashuku","sequence":"first","affiliation":[{"name":"Division of Hematology, Uji-Tokushukai Medical Center, Uji 611-0041, Kyoto, Japan"},{"name":"Department of Laboratory Medicine, Uji-Tokushukai Medical Center, Uji 611-0041, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyako","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Uji-Tokushukai Medical Center, Uji 611-0041, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Uji-Tokushukai Medical Center, Uji 611-0041, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Anzai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Uji-Tokushukai Medical Center, Uji 611-0041, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/WNO.0b013e31820a204e","article-title":"Presence of Erdheim-Chester disease and Langerhans cell histiocytosis in the same patient: A report of 2 cases","volume":"31","author":"Pineles","year":"2011","journal-title":"J. Neuroophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1007\/s00277-022-04998-2","article-title":"Preceding polydipsia\/polyuria, ataxia, and dysarthria in an adult with mixed histiocytosis (Erdheim Chester disease\/Langerhans cell histiocytosis)","volume":"101","author":"Miyoshi","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.2019003507","article-title":"Erdheim-Chester disease: Consensus recommendations for evaluation, diagnosis, and treatment in the molecular era","volume":"135","author":"Goyal","year":"2020","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1093\/neuonc\/noab107","article-title":"Histiocytosis and the nervous system: From diagnosis to targeted therapies","volume":"23","author":"Idbaih","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3390\/neurolint14030060","article-title":"Erdheim-Chester Disease with Isolated CNS Involvement: A Systematic Review of the Literature","volume":"14","author":"Haque","year":"2022","journal-title":"Neurol. Int."},{"key":"ref_7","first-page":"e140","article-title":"Clinical Reasoning: A 52-year-old man with diplopia and ataxia","volume":"87","author":"Bradshaw","year":"2016","journal-title":"Neurology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/jnen\/nlx095","article-title":"CNS Erdheim-Chester Disease: A Challenge to Diagnose","volume":"76","author":"Pan","year":"2017","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1212\/CPJ.0000000000000617","article-title":"Erdheim-Chester disease presenting with chorea and mimicking IgG4-related disorder","volume":"9","author":"Miron","year":"2019","journal-title":"Neurol. Clin. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105841","DOI":"10.1016\/j.clineuro.2020.105841","article-title":"Erdheim-Chester disease: A challenging diagnosis for an effective therapy","volume":"194","author":"Todisco","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/mdc3.12891","article-title":"Choreo-Athetosis and Ataxia as Leading Features in a Case of Erdheim-Chester Disease","volume":"7","author":"Marano","year":"2020","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e228280","DOI":"10.1136\/bcr-2018-228280","article-title":"Vemurafenib as first-line therapy in BRAF-V600E-mutant Erdheim-Chester disease with CNS involvement","volume":"12","author":"Ruiz","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_13","first-page":"vdaa024","article-title":"Dual BRAF\/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy","volume":"2","author":"Mazor","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/pme-2023-0137","article-title":"Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: A case report","volume":"21","author":"Yuen","year":"2024","journal-title":"Pers. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.mayocpiqo.2018.05.001","article-title":"Dabrafenib and Trametinib Treatment for Erdheim-Chester Disease With Brain Stem Involvement","volume":"2","author":"Plate","year":"2018","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.14740\/jh1030","article-title":"Dramatic Response After Switching MEK Inhibitors in a Patient With Refractory Mixed Histiocytosis","volume":"11","author":"Roeser","year":"2022","journal-title":"J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11910-017-0773-7","article-title":"Clippers","volume":"17","author":"Zalewski","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1971400917710251","article-title":"Misdiagnosis: CNS Erdheim-Chester disease mimicking CLIPPERS","volume":"31","author":"Berkman","year":"2018","journal-title":"Neuroradiol. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12185-012-1245-0","article-title":"Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group","volume":"97","author":"Morimoto","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Niazi, S.K. (2023). Non-Invasive Drug Delivery across the Blood-Brain Barrier: A Prospective Analysis. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15112599"},{"key":"ref_23","first-page":"1137","article-title":"Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders","volume":"109","author":"Cournoyer","year":"2024","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/mdc3.12277","article-title":"Neurohistiocytosis of the Cerebellum: A Rare Cause of Ataxia","volume":"3","author":"Elkouzi","year":"2015","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.3324\/haematol.2017.185298","article-title":"Single-agent dabrafenib for BRAFV600E-mutated histiocytosis","volume":"103","author":"Bhatia","year":"2018","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102658","DOI":"10.1016\/j.eclinm.2024.102658","article-title":"Long-term outcome and prognosis of mixed histiocytosis (Erdheim-Chester disease and Langerhans Cell Histiocytosis)","volume":"73","author":"Pegoraro","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","article-title":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","volume":"25","author":"Durham","year":"2019","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2020005803","article-title":"Management of ECD: The era of targeted therapies","volume":"135","author":"Abla","year":"2020","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.18964","article-title":"Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms","volume":"203","author":"Reiner","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Garutti, M., Bergnach, M., Polesel, J., Palmero, L., Pizzichetta, M.A., and Puglisi, F. (2022). BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15010141"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/CMR.0000000000000770","article-title":"Retrospective analysis of adjuvant therapy using dabrafenib plus trametinib in Japanese patients with advanced melanoma: Analysis of 36 cases","volume":"31","author":"Amagai","year":"2021","journal-title":"Melanoma Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ndt\/gfaa372","article-title":"Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib","volume":"37","author":"Seethapathy","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/hep.28692","article-title":"Vemurafenib-induced granulomatous hepatitis","volume":"65","author":"Spengler","year":"2017","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102374","DOI":"10.1016\/j.jaccas.2024.102374","article-title":"Heart Failure with Reduced Ejection Fraction in a Patient with Erdheim-Chester Disease on Dabrafenib","volume":"29","author":"Severdija","year":"2024","journal-title":"JACC Case Rep."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/9\/1\/18\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:09:58Z","timestamp":1767787798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/9\/1\/18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["reports9010018"],"URL":"https:\/\/doi.org\/10.3390\/reports9010018","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]}}}